AlphAIalphai — Financial news for AI agents
GlobeNewswireNOV 183 min read$BCTX

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW ) ( TSX: BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to ...

Original reporting
GlobeNewswire · BriaCell Therapeutics Corp.
Published Nov 18, 2025, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 18, 2025, 2:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$BCTXBullishMed
01

Why it matters

Positive clinical data can enhance investor confidence, potentially leading to stock appreciation. Conversely, any negative or inconclusive results could result in stock decline.

02

Market read

The event is highly relevant for biotech investors, especially those focused on oncology and immunotherapy sectors.

03

What to watch

Potential delays in data release or regulatory hurdles could negatively impact stock performance.

Timing: Upcoming event in November 2025

Background

BriaCell is a clinical-stage biotech focusing on immunotherapies for cancer. The upcoming presentation at SABCS 2025 is a key milestone for validating its clinical progress.

Company-level read

Ticker impact

$BCTXBullishHigh confidence
Context

Biotech sector, specifically cancer immunotherapies

Expected impact

Moderate upward movement in BCTX stock price over the next 1-3 months.

Evidence & confidence

The presentation of clinical data at a major conference often leads to increased visibility and validation of the company's technology, which can positively influence stock performance.

Market effects

Sector

Potential positive impact on biotech and immunotherapy sectors

Regional

Limited regional impact, primarily affecting North American biotech stocks

Global

Moderate, as the event may attract international investor attention

Counterpoint

What could challenge this read

The clinical data presentation may not lead to a significant stock movement if results are not as positive as anticipated.

Key entities

  • Company
    BriaCell Therapeutics Corp.

    Developer of immunotherapies for cancer treatment.

  • Event
    SABCS 2025

    San Antonio Breast Cancer Symposium, a major conference for oncology research.

Read at source← All news

Related articles

JUN 1
$BCTXMedAI 9/10

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics reported positive ASCO 2026 data for Bria-IMT in heavily pretreated metastatic breast cancer. Phase 2 results cited by the company showed 55% survival beyond 1 year and 27% beyond 2 years with the Phase 3-selected regimen; TWiST and quality-of-life analyses from the ongoing Phase 3 Bria-ABC study indicated meaningful benefit with no unexpected safety signals.

manilatimes.net6 min
MAY 26
$BCTXHighAI 9/10

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (Nasdaq: BCTX; TSX: BCT) said its independent Data Safety Monitoring Board reviewed safety data from its pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer and raised no safety concerns, recommending continuation without modifications. The DSMB issued its sixth consecutive positive recommendation; the study is under FDA Fast Track.

manilatimes.net2 min
AUG 28
$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

yahoo.com3 min
AUG 28
$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi

wisbusiness.com3 min
AUG 28
$EXCMed

Why Exelon's CFO is stepping into a new strategy role

Exelon's CFO Jeanne Jones transitions to a new role as EVP of finance and strategy on Oct. 5, focusing on long-term strategy and capital allocation. Robert Kleczynski will succeed Jones as CFO. Exelon reported Q2 revenue of $5.97 billion, up 10% YoY, beating estimates. The company is investing in infrastructure amid rising electricity demand and pressure to keep customer bills affordable.

fortune.com2 min